MA54289A - Analogues deutérés d'acétyl-leucine - Google Patents

Analogues deutérés d'acétyl-leucine

Info

Publication number
MA54289A
MA54289A MA054289A MA54289A MA54289A MA 54289 A MA54289 A MA 54289A MA 054289 A MA054289 A MA 054289A MA 54289 A MA54289 A MA 54289A MA 54289 A MA54289 A MA 54289A
Authority
MA
Morocco
Prior art keywords
leucine
acetyl
deuterated analogs
deuterated
analogs
Prior art date
Application number
MA054289A
Other languages
English (en)
Inventor
Michiko Mann
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA54289A publication Critical patent/MA54289A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054289A 2018-12-06 2019-12-06 Analogues deutérés d'acétyl-leucine MA54289A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776297P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
MA54289A true MA54289A (fr) 2021-10-06

Family

ID=68887086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054289A MA54289A (fr) 2018-12-06 2019-12-06 Analogues deutérés d'acétyl-leucine

Country Status (13)

Country Link
US (2) US12145899B2 (fr)
EP (1) EP3886986A1 (fr)
JP (3) JP7471298B2 (fr)
KR (2) KR102765448B1 (fr)
CN (2) CN120157593A (fr)
AU (1) AU2019391434B2 (fr)
BR (1) BR112021010923A2 (fr)
IL (2) IL283673B2 (fr)
MA (1) MA54289A (fr)
MX (2) MX2021006559A (fr)
SA (1) SA521422185B1 (fr)
SG (1) SG11202106009TA (fr)
WO (1) WO2020115715A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (fr) 2020-01-13 2021-07-22 Intrabio Ltd Traitement de maladies neurodégénératives tardives chez des porteurs de mutations hétérozygotes du gène npc1
WO2022264037A1 (fr) * 2021-06-14 2022-12-22 Intrabio Ltd. Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie
WO2025166100A1 (fr) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions et méthodes de traitement de troubles neurodéveloppementaux

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CN103188933A (zh) * 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
JP6704252B2 (ja) 2013-02-05 2020-06-03 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
PT3482754T (pt) * 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
PT3600276T (pt) 2017-03-28 2023-07-11 Intrabio Ltd Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
EP3697406A1 (fr) 2017-10-18 2020-08-26 IntraBio Ltd Agents thérapeutiques pour mobilité et fonction cognitive améliorées et pour le traitement de maladies neurodégénératives et de troubles de stockage lysosomal
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) * 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN109448569A (zh) * 2018-12-17 2019-03-08 武汉华星光电半导体显示技术有限公司 显示面板
CN119097618A (zh) 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) * 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (fr) * 2020-01-13 2021-07-22 Intrabio Ltd Traitement de maladies neurodégénératives tardives chez des porteurs de mutations hétérozygotes du gène npc1
KR20230015433A (ko) * 2020-05-22 2023-01-31 인트라바이오 리미티드 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물

Also Published As

Publication number Publication date
US20250129011A1 (en) 2025-04-24
IL283673B2 (en) 2025-08-01
MX2021006559A (es) 2021-08-16
CN120157593A (zh) 2025-06-17
JP7471298B2 (ja) 2024-04-19
JP2022514823A (ja) 2022-02-16
JP2024095769A (ja) 2024-07-10
BR112021010923A2 (pt) 2021-08-24
MX2024005670A (es) 2024-05-30
SA521422185B1 (ar) 2024-04-24
CA3122223A1 (fr) 2020-06-11
US20220024858A1 (en) 2022-01-27
KR20210111757A (ko) 2021-09-13
WO2020115715A1 (fr) 2020-06-11
JP2026016521A (ja) 2026-02-03
IL283673B1 (en) 2025-04-01
AU2019391434B2 (en) 2025-01-09
KR20250022899A (ko) 2025-02-17
IL283673A (en) 2021-07-29
SG11202106009TA (en) 2021-07-29
CN113348018A (zh) 2021-09-03
CN113348018B (zh) 2025-04-01
IL319687A (en) 2025-05-01
AU2019391434A1 (en) 2021-07-08
EP3886986A1 (fr) 2021-10-06
US12145899B2 (en) 2024-11-19
KR102765448B1 (ko) 2025-02-07

Similar Documents

Publication Publication Date Title
EP3870593A4 (fr) Analogues nucléotidiques
IL283385A (en) Modified gip peptide analogues
MA46180A (fr) Analogues de l'amyline
EP3328827A4 (fr) Promédicaments d'analogues de glutamine
EP3820473A4 (fr) Synthèse enzymatique d'analogues de nucléosides de type 4'-éthynyle
EP3860449A4 (fr) Agencement d'électrodes
UA42295S (uk) Комп'ютер
IL283673A (en) Deuterated analogs of acetyl-leucine
MA53085A (fr) Thiophènecarboxamides substitués et analogues comme agents antibactériens
EP3846791A4 (fr) Analogues d'illudine, utilisations associées et leurs procédés de synthèse
MA50047A (fr) Administration orale d'analogues peptidiques de glp-1
EP3325487A4 (fr) Préparation pour analogues d'anticholinergiques à potentiel modéré
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
MX383647B (es) Análogos deuterados de etifoxina, sus derivados y usos de estos.
EP3752149A4 (fr) Analogues de quinolone, sels correspondants, compositions et procédé d'utilisation
EP3472176A4 (fr) L'utilité de (+) épicatéchine et de leurs analogues
EP3627775A4 (fr) Synchronisation d'itinéraire
PL3898602T3 (pl) Synteza 3-metylo-1,2,4-tiadiazolo-5-karbohydrazydu lub jego metylo-d3 deuterowanej postaci
EP3920962A4 (fr) Purification d'analogues de glp-1
SI3512495T1 (sl) Formulacije prostaciklinskih analogov
EP3891220A4 (fr) Mélanges d'élastomères thermoplastiques fluorés
DK3886813T3 (da) Farmaceutiske formuleringer af cyclosporinanaloger
EP4426673A4 (fr) Analogues de la pentamidine
ZA202006370B (en) Deuterated analogs of elacridar
EP3906225C0 (fr) Analogues de pantothénamide